A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission.

Prior treatment

• Recent major cardiovascular events such as an acute coronary syndrome, CABG, stroke or TIA in the 90 days before screening
• Any sustained ventricular arrythmias within 6 months prior to screening

Other illness

• Albuminuric chronic kidney disease
• Uncontrolled hypertension
• Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute
• Patients with a cardiac resynchronization therapy device who have < 98% biventricular pacing during screening
• Any untreated valvular heart disease of moderate or greater severity during screening.

Age

• Presence of any other disease with a life expectancy of < 2 years.

Other

• Pregnant or lactating women.

• Adults aged ≥ 18 years
• Heart failure in remission, defined as heart failure with an improved ejection fraction to an LVEF above 50%, with normalized LV volumes, an NT-proBNP ≤ 250 pg/mL, normal functional capacity, and clinical stability
• Patients must receive at least 3 HF therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i) for HF, consistent with international HF guidelines. Each therapy must have been titrated to the maximally tolerated dose, stable for at least 6 months prior to screening